Search results

Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.

Result type

Technology appraisal guidance

Published

9 March 2022

Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Last updated

23 November 2016

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

Result type

Technology appraisal guidance

Published

24 February 2021

Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

Result type

Technology appraisal guidance

Published

21 June 2023

Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

25 May 2016

In development [GID-TA11547] Expected publication date: TBC

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

Result type

Technology appraisal guidance

Published

1 November 2023

Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

Result type

Technology appraisal guidance

Published

9 March 2022

Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

27 March 2019

Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic kidney disease in adults.

Result type

Technology appraisal guidance

Published

20 December 2023

Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

5 June 2019

This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

Result type

NICE guideline

Last updated

29 June 2022

Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

25 June 2014

Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

Result type

Technology appraisal guidance

Published

25 March 2015